ED / HSDD / low libido

Unlike PDE5 inhibitors it acts centrally, not on penile vasculature: MC4R agonism in the hypothalamus and medial preoptic area drives the pro-desire/pro-arousal signal upstream of the physical response, which is why it targets desire and distress rather than just rigidity.

Strong for female HSDD: the approval review summarizes the phase 3 RECONNECT program, and a phase 2b dose-ranging RCT showed statistically significant gains in desire and reductions in desire-related distress at 1.75 mg SC, though effect sizes are modest. In men, evidence is thinner: a small randomized crossover pilot (19 men) showed intranasal PT-141 plus low-dose sildenafil produced greater erectile response than sildenafil alone, so the male/combination use is best described as emerging rather than established.

Anecdotal community signal only for off-label use: men and women source PT-141 from research-peptide vendors and self-inject subcutaneously on-demand before intimacy, commonly reporting increased desire and spontaneous arousal within 1-3 hours, plus a subset reporting strong nausea and transient flushing. Widely discussed on peptide and men's-health forums; none of this substitutes for the controlled female HSDD data.

Context, not a protocol: the FDA-approved female dose is 1.75 mg SC as needed, no more than one dose per 24 hours and up to 8 per month, discontinued after 8 weeks if no benefit. Community male dosing is typically lower (often 1-2 mg SC) and titrated to limit nausea.

Transient blood pressure rise and heart-rate changes make uncontrolled hypertension or significant cardiovascular disease a real concern; focal hyperpigmentation can occur with repeated use. Nausea is common enough to limit adherence. Combining with PDE5 inhibitors (the male use case) compounds hemodynamic effects and warrants caution.

• Bremelanotide: New Drug Approved for Treating Hypoactive Sexual Desire Disorder. ↗
• Responder Analyses from a Phase 2b Dose-Ranging Study of Bremelanotide. ↗
• Co-administration of low doses of intranasal PT-141, a melanocortin receptor agonist, and sildenafil to men with erectile dysfunction results in an enhanced erectile response. ↗
• Hypoactive Sexual Desire Disorder in Women: Physiology, Assessment, Diagnosis, and Treatment. ↗

Beyond its role driving GnRH and the reproductive axis, kisspeptin modulates limbic and sexual-processing brain circuits; the rationale for low libido is enhancement of the central appetitive/arousal network rather than any peripheral vascular effect.

Emerging: a double-blind, placebo-controlled crossover RCT in men with HSDD (32 completers) showed kisspeptin-54 infusion significantly modulated sexual brain processing on fMRI with increased penile tumescence and behavioral desire measures. Two earlier randomized crossover fMRI studies in healthy men showed enhanced limbic responses to sexual/bonding stimuli and to attraction cues, with the largest effect in men with lower sexual quality of life. All are small, mechanism-rich, single-center, and use IV infusion, so this is early human signal, not clinical proof.

Anecdotal community signal is limited and cautious: kisspeptin-10 is sold by research-peptide vendors and a small number of biohackers experiment with subcutaneous dosing for libido/testosterone effects, but reports are sparse and inconsistent, and community half-life/route differs sharply from the IV infusions used in trials. Treat any 'it works' anecdote as very low-quality.

Context, not a protocol: trials used IV kisspeptin-54 infusion (e.g., ~1 nmol/kg/h); there is no validated subcutaneous or intranasal dose for sexual dysfunction, and community kisspeptin-10 dosing has no evidentiary basis.

As a master regulator of the reproductive axis, chronic or repeated exposure risks receptor desensitization and unpredictable HPG-axis effects; interactions with fertility treatment and hormonal therapy are plausible and unstudied. No long-term human safety data for a low-libido indication.

• Effects of Kisspeptin on Sexual Brain Processing and Penile Tumescence in Men With Hypoactive Sexual Desire Disorder: A Randomized Clinical Trial. ↗
• Kisspeptin modulates sexual and emotional brain processing in humans. ↗
• Kisspeptin enhances brain responses to olfactory and visual cues of attraction in men. ↗

Centrally, oxytocin is released around arousal and orgasm and is implicated in pair-bonding, trust, and sexual reward, giving a rationale for desire and satisfaction; peripherally, vaginal oxytocin acts locally on the mucosa, which is the mechanism most relevant to the postmenopausal trial (tissue/atrophy) rather than central desire.

Emerging but weak: a randomized placebo-controlled trial of vaginal oxytocin gel (400 IU) in 96 postmenopausal women improved vaginal maturation index and all Female Sexual Function Index domains including desire, but the effect is confounded by improvement in vulvovaginal atrophy, so it speaks more to genitourinary syndrome of menopause than to primary low libido. The male evidence is a single case report of broad sexual improvement on intranasal oxytocin used for social anxiety. Grade honestly sits at the low end of emerging.

Anecdotal community signal: intranasal oxytocin is used off-label by couples and biohackers as a 'connection'/pre-intimacy aid, with users reporting warmth, closeness, and sometimes heightened arousal; sublingual troches are also marketed. Reports are subjective, placebo-prone, and inconsistent, and should not be read as efficacy for a desire disorder.

Context, not a protocol: the trial used 400 IU vaginal gel; community intranasal use is typically in the ~20-40 IU range dosed shortly before intimacy. Neither is a validated protocol for HSDD.

Vaginal oxytocin's benefit in the trial overlaps heavily with treating atrophy, so it is not interchangeable with a central desire agent; intranasal absorption and CNS delivery are variable. Uterine-stimulant activity makes it inappropriate in pregnancy, and long-term data for sexual indications are absent.

• The Impact of Oxytocin Vaginal Gel on Sexual Function in Postmenopausal Women: A Randomized Controlled Trial. ↗
• Dramatic improvement in sexual function induced by intranasal oxytocin. ↗

Like PT-141 it activates central melanocortin pathways (including MC4R) to drive erection and arousal, but its non-selectivity across MC1R/MC3R/MC4R/MC5R accounts for its off-target tanning, appetite, and pigmentary effects and makes it a blunter tool than the MC4R-focused bremelanotide it was refined into.

Preclinical/early-clinical: the supporting review summarizes basic research and early clinical work showing melanocortin agonists (melanotan I/II, bremelanotide) induce erection and arousal, but the definitive controlled trials were carried forward in bremelanotide, not melanotan II itself. There is no modern RCT establishing melanotan II as a treatment for ED or HSDD; the case for it is inferred from its class and its role as bremelanotide's parent compound.

Anecdotal community signal is substantial: melanotan II is widely sold as an unregulated research/tanning peptide and self-injected subcutaneously, with many users reporting spontaneous erections and increased libido as a prominent 'side effect,' alongside nausea, flushing, darkening of moles, and new pigmented lesions. This is a large but entirely uncontrolled real-world signal, not evidence of a favorable benefit-risk profile.

Context, not a protocol: community subcutaneous dosing is typically in the ~0.25-1 mg range, often micro-dosed to limit nausea; there is no approved or trial-validated dose for sexual dysfunction.

Melanocortin activation drives melanogenesis, so darkening of existing nevi and appearance of new pigmented lesions is a specific concern, with case reports of changing melanocytic lesions and melanoma in users; unregulated product purity is an added hazard. It shares the nausea and blood-pressure effects of the melanocortin class. If a melanocortin effect is wanted, the selective, tested bremelanotide is the rational choice.

• Melanocortin receptor agonists in the treatment of male and female sexual dysfunctions: results from basic research and clinical studies. ↗

It targets the vascular arousal pathway, not central desire: by inhibiting PDE5 it prevents cGMP breakdown in penile smooth muscle, sustaining nitric-oxide-mediated vasodilation and erection in response to sexual stimulation. Its ~17.5-hour half-life allows both on-demand and daily dosing.

Strong: a systematic review and meta-analysis of 16 controlled trials directly comparing tadalafil with sildenafil found comparable efficacy and overall adverse-event rates, with tadalafil showing better psychological outcomes and greater patient and partner preference. This sits on top of decades of RCT and regulatory data establishing PDE5 inhibitors as first-line ED therapy.

Anecdotal community signal: daily low-dose tadalafil ('5 mg daily' or micro-dosed 2.5 mg) is popular off the on-demand label for spontaneity and is widely used by biohackers who also cite putative benefits for endothelial function, LUTS, and 'pump.' Users report reliable response; because a daily dose is itself FDA-approved, this maps onto an approved indication and is less speculative than most community use here.

Context, not a protocol: on-demand 10 mg (range 5-20 mg) taken before activity, or daily 2.5-5 mg for spontaneity; effect window extends over 24-36 hours, the basis of the 'weekend' nickname.

Absolutely contraindicated with any nitrate and with the guanylate-cyclase stimulator riociguat due to profound hypotension; use caution with alpha-blockers and other antihypertensives. Note that PDE5 inhibitors treat the vascular/erectile component only and do nothing for the desire deficit central to HSDD/low libido.

• Direct comparison of tadalafil with sildenafil for the treatment of erectile dysfunction: a systematic review and meta-analysis. ↗